Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
about
Novel histone deacetylase inhibitors in clinical trials as anti-cancer agentsMonitoring the effect of belinostat in solid tumors by H4 acetylationCancer of the Pancreas: Molecular Pathways and Current Advancement in TreatmentEpigenetic regulators and their impact on therapy in acute myeloid leukemiaNovel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic)Trials with 'epigenetic' drugs: an updateMitochondrial apoptosis and FAK signaling disruption by a novel histone deacetylase inhibitor, HTPB, in antitumor and antimetastatic mouse modelsPanobinostat synergistically enhances the cytotoxic effects of cisplatin, doxorubicin or etoposide on high-risk neuroblastoma cellsPanobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51Activation of HIV transcription with short-course vorinostat in HIV-infected patients on suppressive antiretroviral therapyProteomic Analysis of HDAC3 Selective Inhibitor in the Regulation of Inflammatory Response of Primary MicrogliaHistone Deacetylase Inhibitor Romidepsin Has Differential Activity in Core Binding Factor Acute Myeloid LeukemiaClinical Toxicities of Histone Deacetylase Inhibitors.Phase II study of the histone deacetylase inhibitor belinostat (PXD101) for the treatment of myelodysplastic syndrome (MDS).Emerging therapies for acute myeloid leukemia.Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T-cell lymphomaHistone deacetylase inhibitors induce apoptosis in human eosinophils and neutrophils.What are the endpoints of therapy for acute leukemias? Old definitions and new challenges.Inhibition of histone deacetylases 1 and 6 enhances cytarabine-induced apoptosis in pediatric acute myeloid leukemia cells.Phase 1 study of the oral isotype specific histone deacetylase inhibitor MGCD0103 in leukemia.Combination therapy in combating cancer.Deregulation of HDAC1 by p25/Cdk5 in neurotoxicityHistone deacetylase inhibitors: molecular mechanisms of action and clinical trials as anti-cancer drugs.Leukaemogenesis: more than mutant genesThe cytoplasmic deacetylase HDAC6 is required for efficient oncogenic tumorigenesis.Epigenetic therapy of acute myeloid leukemia using 5-aza-2'-deoxycytidine (decitabine) in combination with inhibitors of histone methylation and deacetylation.Histone deacetylase (HDAC) inhibitors in recent clinical trials for cancer therapy.Evaluation of the pharmacodynamic effects of MGCD0103 from preclinical models to human using a novel HDAC enzyme assay.Synergistic antitumor interactions between MK-1775 and panobinostat in preclinical models of pancreatic cancer.Myelodysplastic syndrome and histone deacetylase inhibitors: "to be or not to be acetylated"?Interpreting clinical assays for histone deacetylase inhibitors.Dose study of the multikinase inhibitor, LY2457546, in patients with relapsed acute myeloid leukemia to assess safety, pharmacokinetics, and pharmacodynamicsEpigenetic priming of AML blasts for all-trans retinoic acid-induced differentiation by the HDAC class-I selective inhibitor entinostat.Translational phase I trial of vorinostat (suberoylanilide hydroxamic acid) combined with cytarabine and etoposide in patients with relapsed, refractory, or high-risk acute myeloid leukemiaIdentification of histone deacetylase inhibitors with benzoylhydrazide scaffold that selectively inhibit class I histone deacetylases.The histone deacetylase inhibitor entinostat (SNDX-275) induces apoptosis in Hodgkin lymphoma cells and synergizes with Bcl-2 family inhibitors.Histone deacetylase inhibition decreases proliferation and potentiates the effect of ionizing radiation in atypical teratoid/rhabdoid tumor cells.Vorinostat approved in Japan for treatment of cutaneous T-cell lymphomas: status and prospects.Histone deacetylase inhibitors: clinical implications for hematological malignancies.The histone deacetylase inhibitor belinostat (PXD101) suppresses bladder cancer cell growth in vitro and in vivo
P2860
Q21198868-F3FF0457-1F8C-489F-8D5B-A16F1BAD776BQ24644030-94436063-2B82-4D12-91F7-94ABF6845100Q26740619-F389E6F6-406E-4C1D-AFB0-E76711C491BCQ26765402-15708A94-4906-4A89-B0F7-CDD80551CA8FQ26770391-ACA0F851-9D86-4642-A0CA-F2D535BA483CQ27000542-CE90A2BF-F7C9-4C88-ADB9-627256306DD9Q27310013-A218051C-49D7-48E9-9E91-9A7EDA3BA3C8Q28533896-C606ED97-4DD9-4052-A591-9C4F1421C18EQ28535006-42AB6789-8B37-4833-8FD5-9C34A43D2CA0Q28544949-BEB010D9-0586-46F4-8203-28A9CDB80247Q29048635-6FCB21F9-DA4F-4F2E-AD6E-3C9C8921556FQ29394054-DB2AD941-0E02-495A-ACC6-48B0EF4D1438Q31135325-FDD451C2-D85C-45B0-944B-2D8E728AC831Q33395173-A316BC59-7A7C-4B51-835D-25A8BB107FD3Q33576363-26D1EEFE-E68A-4729-86C5-5472A82FF7CEQ33726989-C6005804-834D-4D7E-88F3-ED10E5BE2AC0Q33737214-200DF097-38B4-40F6-952C-EB578DE395B5Q33775647-21ACED5E-3FDB-45A4-A8FC-E150F46168A4Q33831971-80611217-EEB2-4E74-A3F8-F2CE05D2B602Q33844751-102B9461-B4FE-41EB-974D-77BCCAE5FE4DQ33914234-CEB06F8B-6BD0-4D17-A0D8-C25E9CEC60B8Q34028507-1C552B94-2533-418E-B577-BED29EF19D90Q34171631-FE329E87-744E-4F8C-BECF-4CBED68D235CQ34275371-BFE3E961-E7B7-40EC-ACAB-A5EB15F8C5F0Q34296908-FACAF851-F322-4F59-9F78-E0168AEA9DF4Q34326174-3C17704B-AB1B-48EE-9E77-8B89F9AD974FQ34488424-96BEC3E1-FCB3-4714-B374-70594BEE7F16Q34656429-D7AC945C-24EF-43FE-B5DF-FD762EDAEA55Q34808616-10A2AF33-F979-43A1-83AD-472CAD6D81C7Q35001132-F24C4D4A-5ACB-44CC-9529-8D8DFB768BF2Q35003657-820AC32C-6FC4-4B47-AB86-2328C8B122D4Q35003666-281CCF18-08E6-4012-A2E5-E4A9D4616681Q35014402-F979CD4B-8285-463F-90A9-7AACDEA5DCFFQ35096240-2078DA11-DFA2-431C-9671-628D095F3060Q35194759-DDEEB650-5A48-456F-8F27-B5F6546D6795Q35223868-FDAC8352-4681-4714-A4D0-1B795157EA76Q35696415-9EFB28FC-B647-4EB4-A657-D56DC26245B3Q35939690-C05DFBB8-B2D6-41CA-BD06-0D10A2A3FF5FQ36001847-59C5BBE8-D4AA-484C-AF50-AA8098EF800EQ36178061-AC021DCC-C079-4E28-A896-28BEBB21EB2A
P2860
Phase 1 and pharmacologic study of MS-275, a histone deacetylase inhibitor, in adults with refractory and relapsed acute leukemias.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Phase 1 and pharmacologic stud ...... and relapsed acute leukemias.
@ast
Phase 1 and pharmacologic stud ...... and relapsed acute leukemias.
@en
type
label
Phase 1 and pharmacologic stud ...... and relapsed acute leukemias.
@ast
Phase 1 and pharmacologic stud ...... and relapsed acute leukemias.
@en
prefLabel
Phase 1 and pharmacologic stud ...... and relapsed acute leukemias.
@ast
Phase 1 and pharmacologic stud ...... and relapsed acute leukemias.
@en
P2093
P2860
P1433
P1476
Phase 1 and pharmacologic stud ...... and relapsed acute leukemias.
@en
P2093
Anchalee Jiemjit
Edward A Sausville
Eun Joo Chung
Ivana Gojo
Jacqueline Greer
James Zwiebel
Jane B Trepel
Judith E Karp
Michael L Tidwell
Min-Jung Lee
P2860
P304
P356
10.1182/BLOOD-2006-05-021873
P407
P577
2007-04-01T00:00:00Z